Machine learning methods identified top predictors of coronary artery burden in patients with psoriasis, which were markers related to obesity, dyslipidemia, and inflammation, demonstrating that these are potentially important comorbidities to treat in psoriasis.
A new guideline addresses important clinical questions that arise in psoriasis management and provides evidence-based recommendations for treating pediatric patients with psoriasis.
The first study to compare the real-world survival of a single biologic administered in-office with the same agent administered at home suggests that in-office ustekinumab administration may result in superior drug survival.
Participation in 4 therapy seminars resulted in appreciable improvement in pruritus in patients with atopic dermatitis or psoriasis and may be an efficient supplementary method for managing chronic itch in these populations.
Despite well-established associations of psoriasis and atopic dermatitis with depression and suicidality, and recommendations for increased screening in these higher-risk patients, clinical practice gaps remain, with low rates of depression screening.
UCB announced positive results from the phase 3 BE SURE study of bimekizumab in the treatment of adults with moderate-to-severe plaque psoriasis compared with adalimumab.
Adalimumab 0.8 mg/kg every other week was effective in a population of children and adolescents affected by moderate to severe plaque psoriasis, results of a real-life clinical experience show.
The five-year incidence rate of joint surgery in psoriatic arthritis patients is twice as high as in the general population, and this rate has remained steady over time.
The FDA has approved RediTrex (methotrexate injection; Cumberland) for the management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis, who are intolerant of or had an inadequate response to first-line therapy.
Treatment with biologics for psoriasis is not the same for men and women, a study shows, and may explain why women tend toward earlier discontinuation with biologic treatment.
